The conference call can be accessed using the following information: Webcast: Click here Date: Wednesday, August 13, 2025 – 4:30 p.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 ...

Total revenue of $8.5 million in the second quarter of 2025, a decrease of 18% over the second quarter of 2024. MaxCyte added two new SPL clients, Adicet Bio and Anocca AB, in July. Including TG ...

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

Second quarter 2025 selling, general and administrative expenses increased by $0.7 million year-over-year, to $9.7 million (from $9.0 million). The increase was primarily driven by higher sales ...

Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT. EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the pare ...

Neumora is currently conducting preclinical DIO studies to characterize the potential of NMRA-215 in obesity and expects to report data in 2025. Additionally, Neumora expects to progress NMRA-215 into ...

Cytek will host a conference call to discuss its second quarter 2025 financial results on Wednesday, August 6, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference ...

Net Loss. Net loss totaled $21.3 million for the three months ended June 30, 2025, as compared to net loss of $17.8 million for the three months ended June 30, 2024, with non-cash stock-based ...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following ...

“We’re thrilled to welcome Dr. Tarnoff to our Board during this pivotal phase of growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “His leadership and expertise in clinical ...

Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4 ...

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...